Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 9, 2026
Acadia held Federal Circuit oral arguments on the NUPLAZID 34 mg formulation patent appeal, with a decision expected in the first half of 2027.
Nasdaq: $ACADBiotech · NeuroscienceClinical and patent risk
ACAD Stock Hub: Acadia Pharmaceuticals News, DAYBUE and Remlifanserin
Acadia generated $342.291 million of Q3 revenue from NUPLAZID and DAYBUE products, with $976.446 million of cash and investments at September 30. The next scheduled catalyst is the November 17 RADIANT presentation at CTAD, following a Phase 2 result that missed its primary endpoint. The NUPLAZID formulation-patent appeal was heard November 9; Acadia expects a decision in the first half of 2027 without a fixed court deadline. Commercial growth provides resources for the pipeline, while clinical confirmation, patent duration and reimbursement remain material risks.
Research Library · Biotech
Acadia: commercial growth and the neuroscience pipeline
Clinical endpoints, financial statements, capital, patents, governance and risks.
Next catalyst · Announced presentation
November 17, 2026 · RADIANT at CTAD
OC7 oral presentation at 9:35 a.m. Eastern Time in Boston: Phase 2 remlifanserin efficacy and safety. The September topline missed its primary endpoint. Presentation schedule
Before the presentation: the November 9 patent hearing is complete; Acadia expects the appeal decision in the first half of 2027. A separate biomarker poster follows November 18.
ACAD stock data: product sales, cash and capital
Regular close
$18.37
November 11, 2026
Calculated equity value
$3.175B
Close × October 28 common shares
Cash and investments
$976.446M
September 30, 2026 · excludes restricted cash
Q3 revenue
$342.291M
Quarter ended September 30, 2026
NUPLAZID Q3 sales
$202.158M
Net product sales · Q3 2026
DAYBUE Q3 sales
$140.133M
All trofinetide forms · Q3 2026
Operating cash generation
$146.265M
Nine months ended September 30, 2026
Common shares
172.829M
172,828,972 · October 28, 2026
Quarterly filing. Equity value is calculated using the dated close and cover-page common-share count; unissued awards are excluded.
Acadia now: growing products and an unconfirmed clinical signal
RADIANT Phase 2 missed the primary endpoint. At 60 mg, SAPS-H+D changed −12.6 versus −10.4 with placebo at week six (p=0.0603). CGI-S-ADP favored 60 mg with nominal p=0.0077. Acadia continued Phase 3 development; these results are not a completed successful pivotal trial.
▲ The constructive case
Two commercial franchises generated positive operating cash flow. DAYBUE STIX supported growth, DAYBU launched in Germany in October and cash provides flexibility for ongoing development. The 60 mg remlifanserin signal and favorable reported short-term tolerability supported further study.
▼ The cautious case
The RADIANT primary statistical test failed; later studies must establish efficacy and safety. NUPLAZID faces a pending formulation-patent appeal and prospective public-payer pricing changes. International launches, licensed-product payments and equity compensation affect retained economics.
RADIANT topline · Financial position and risks · Patent and pricing expectations.
Latest ACAD news
Nov 9, 2026
Acadia Pharmaceuticals comments on Federal Circuit oral argument in NUPLAZID formulation patent appeal
Oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the District of Delaware's May 2025 decision upholding U.S. Patent No. 11,452,721, which covers the NUPLAZID 34 mg capsule formulation. Acadia expects a Federal Circuit decision in the first half of 2027. If the judgment is upheld, Acadia expects patent protection until February 2038; if not, protection is expected to extend to October 2030.
Nov 9, 2026
Acadia to Present Remlifanserin Data at 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
Acadia Pharmaceuticals announced two presentations at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November 16-19, 2026, in Boston. An oral presentation on the Phase 2 portion of the RADIANT trial program evaluates remlifanserin in patients with Alzheimer's disease psychosis, scheduled for Tuesday, November 17, 2026. A poster presentation on biomarker distribution among patients meeting clinical criteria for Alzheimer's disease psychosis is scheduled for Wednesday, November 18, 2026.
ACAD stock catalysts: CTAD, patent appeal and 2027 trials
- November 17, 2026 · 9:35 a.m. ET — RADIANT Phase 2 efficacy and safety oral presentation at CTAD, Boston. Announced presentation
- November 18, 2026 · 7:15 a.m.–5:30 p.m. ET — P303 poster on biomarker heterogeneity in Alzheimer’s disease psychosis. Announced poster
- First half of 2027 — NUPLAZID formulation-patent appeal decision. Acadia expectation · No court deadline
- Second half of 2027 — ACP-211 Phase 2 NORLIGHT readout in major depressive disorder. Company guidance
- Fourth quarter of 2027 — Remlifanserin Phase 2 ILLUMERA readout in Lewy body dementia psychosis. Company guidance
- 2027 — Planned trofinetide regulatory filing in Japan and ACP-711 Phase 2 initiation. Company development plans
Conference schedule · Appeal timing · Current development outlook. Registry primary-completion estimates differ from company data-release guidance.
Acadia products: NUPLAZID and DAYBUE revenue
PARKINSON’S DISEASE PSYCHOSIS
NUPLAZID · Pimavanserin
Q3 2026 net sales of $202.158 million; nine-month sales of $552.214 million. U.S. approval is for hallucinations and delusions associated with Parkinson’s disease psychosis. The label includes a boxed warning concerning mortality in elderly patients with dementia-related psychosis.
RETT SYNDROME
DAYBUE · Trofinetide
Q3 2026 global net sales of $140.133 million; nine-month sales of $366.098 million across commercial forms. DAYBUE and DAYBUE STIX are approved in the U.S. from age two. DAYBU is authorized in the EU for neurobehavioral symptoms from age five; Germany launched in October.
2026 guidance, November 4: total revenue $1.265–$1.295 billion; NUPLAZID $760–$775 million; DAYBUE products $505–$520 million. These are forecast ranges, not full-year results. Trofinetide’s Japanese Phase 3 study was completed; Acadia planned a 2027 filing and a possible 2028 launch, conditional on approval and commercial preparations.
Product revenue and obligations · Results and guidance · EU authorized indication.
Remlifanserin RADIANT: endpoint, dose and study populations
PHASE 2 · RADIANT
363 randomized
126 at 60 mg, 121 at 30 mg and 116 on placebo. The modified full analysis set was 109/110/107, totaling 326. Safety denominators were 125/120/115, totaling 360. The registry’s 1,074 estimated enrollment covers the broader master protocol.
ONGOING PHASE 3
Focus on 60 mg
Acadia removed 30 mg and refined the statistical plan, site selection and use of central raters. The November presentation specified no change to inclusion criteria. Nominal secondary findings and subgroup analyses do not replace the failed Phase 2 primary endpoint.
OTHER PROGRAMS
ILLUMERA and NORLIGHT
Remlifanserin in Lewy body dementia psychosis: Phase 2 data guided to Q4 2027. ACP-211 in depression: Phase 2 data guided to H2 2027. Remlifanserin’s Fast Track designation in Lewy body dementia psychosis is not approval.
RADIANT populations and results · November program refinements · RADIANT trial · NORLIGHT trial.
Merlintrader Health Score · ACAD
3.80out of 5
Assessment: November 12, 2026. Weighted calculation: 4.5 × 30% + 3.0 × 30% + 4.0 × 20% + 4.0 × 10% + 3.5 × 10% = 3.80 out of 5. The score describes financial and operational resilience over twelve to eighteen months. It is not an indication to buy or sell.
Q3 2026 Form 10-Q · filed November 5 · RADIANT topline announcement · September 24, 2026 · CTAD presentation schedule · November 9, 2026
ACAD red flags
- RADIANT Phase 2 missed the primary endpoint; subsequent pivotal success remains uncertain.
- NUPLAZID formulation-patent appeal remains pending; legal outcomes and protection horizons are conditional.
- Acadia expects NUPLAZID negotiated pricing in 2029; the final economic effect is uncertain.
- Trofinetide gastrointestinal tolerability, weight loss, reimbursement and persistence affect commercial performance.
- International launches and royalty or milestone obligations affect cash retained from revenue.
- Equity compensation and future awards create dilution risk.
- R&D leadership changed October 23 while major clinical studies were under way.
ACAD Stock FAQ: Acadia Pharmaceuticals Questions Answered
When is the next ACAD stock catalyst?
As of November 12, 2026, Acadia scheduled its RADIANT Phase 2 presentation for November 17 at 9:35 a.m. Eastern Time at CTAD in Boston. A biomarker poster follows November 18 from 7:15 a.m. to 5:30 p.m. Eastern Time. The topline findings were announced September 24; these presentations provide additional detail. CTAD presentation schedule · November 9, 2026.
Which Acadia medicines are FDA approved?
As of November 12, 2026, NUPLAZID was FDA-approved for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE and DAYBUE STIX were approved for Rett syndrome from age two. Remlifanserin and ACP-211 remained investigational. In the EU, DAYBU is authorized for neurobehavioral symptoms of Rett syndrome from age five. Q3 2026 Form 10-Q · filed November 5 · DAYBU EU product information · October 12, 2026.
How much cash does Acadia have, and how long will it last?
At September 30, 2026, Acadia had $976.446 million of cash, cash equivalents and investment securities, excluding $7.846 million of restricted cash. Nine-month operating cash generation was $146.265 million. Management expected liquidity and anticipated product sales to fund planned operations through and beyond the next twelve months. Q3 2026 Form 10-Q · filed November 5.
Is ACAD stock exposed to share dilution?
At October 28, 2026, Acadia had 172,828,972 common shares outstanding. Shares increased by 2,480,174 during the first nine months of 2026, approximately 1.46%. Equity awards and future grants can create additional dilution. The quarterly diluted EPS denominator is a weighted average, rather than a current fully diluted share count. Q3 2026 Form 10-Q · filed November 5.
When does Acadia report earnings?
As of November 12, 2026, Acadia had not announced its next earnings date. Its latest results, released November 4, covered the quarter ended September 30. Revenue was $342.291 million and net income was $53.524 million. Full-year 2026 revenue guidance was $1.265 billion to $1.295 billion. Third-quarter results and guidance · November 4, 2026.
What does Acadia Pharmaceuticals do?
As of November 12, 2026, Acadia was a commercial neuroscience and rare-disease company headquartered in San Diego. It sells NUPLAZID for Parkinson’s disease psychosis and trofinetide products for Rett syndrome, while developing investigational medicines including remlifanserin and ACP-211. Its common stock trades on Nasdaq under ACAD. Q3 2026 Form 10-Q · filed November 5.
Did Acadia’s RADIANT trial meet its primary endpoint?
On September 24, 2026, Acadia reported that RADIANT Phase 2 missed statistical significance on its primary SAPS-H+D endpoint: p=0.0603 for 60 mg versus placebo. The CGI-S-ADP secondary endpoint had nominal p=0.0077. Acadia continued Phase 3 development and removed the 30 mg dose arm from its development plan. RADIANT topline announcement · September 24, 2026 · Third-quarter presentation · November 4, 2026.
When is the ACAD NUPLAZID patent appeal decision expected?
As of November 12, 2026, Acadia expected a decision in the first half of 2027, with no fixed court deadline. The Federal Circuit heard appeal 2025-1875 on November 9. Acadia described protection through February 2038 if the formulation-patent judgment is upheld and through October 2030 under an unfavorable outcome, subject to its stated patent assumptions. Federal Circuit appeal 2025-1875 · November 9, 2026 · Acadia patent-appeal commentary · November 10, 2026.
Primary sources
- Q3 2026 Form 10-Q · filed November 5
- Third-quarter results and guidance · November 4, 2026
- 2025 Form 10-K · filed February 26, 2026
- RADIANT topline announcement · September 24, 2026
- RADIANT clinical presentation · September 24, 2026
- Third-quarter presentation · November 4, 2026
- CTAD presentation schedule · November 9, 2026
- Federal Circuit appeal 2025-1875 · November 9, 2026
- Acadia patent-appeal commentary · November 10, 2026
- DAYBU EU product information · October 12, 2026
- FDA DAYBUE prescribing information
- R&D leadership transition · October 23, 2026
- ClinicalTrials.gov · NCT06159673
- ClinicalTrials.gov · NCT07284667
- ClinicalTrials.gov · NCT07029581
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $ACAD or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data or decline to file an application, and companies that spend ahead of revenue raise equity at whatever price the market will bear. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate. Investors may lose part or all of their capital.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
